EMEA-001371-PIP01-12
Key facts
| Active substance |
Clazakizumab
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0029/2014
|
| PIP number |
EMEA-001371-PIP01-12
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
CSL Behring GmbH
Tel. +49 151 44162443 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|